VC: Logical Therapeutics gains $30M in second round



Logical Therapeutics gains $30M in second round

VENTURE CAPITAL

COMPANY

AMOUNT/ROUND

LEAD INVESTORS

DESCRIPTION

Ception Therapeutics
Malvern, PA

$14.7M
Third

Third Point and Greenlight Capital

The company's pipeline includes a late-stage biologic agent in clinical development for multiple inflammatory conditions, a small molecule anti-TNF program and other discovery programs.

Logical Therapeutics
Pittsburgh, PA

$30M
Second

SV Life Sciences

The funding will allow Logical to advance multiple drug candidates, including its lead drug, LT-NS001, a naproxen pro-drug, through proof-of-concept clinical trials.

Suggested Articles

Bausch Health is paying $10 million upfront for the option to acquire Allegro Ophthalmics’ eye disease assets, with a promise of $40 million to come.

Anthony Coyle, Ph.D., has signed up to run Repertoire Immune Medicines’ R&D.

The IPO haul will set Kronos up to start a registrational phase 2/3 trial of a first-line AML drug licensed from Bischofberger's former employer.